RE: Analyst paralysis20 Jul 2022 15:00
Reply from IR I raised a few points made on here…
Thank you for your email.
As you are aware, there are several factors at play influencing any companies share price. Additionally, all recent approaches for THG have been unsolicited, and in the unanimous opinion of the Board, were unacceptable and significantly undervalued the Company.
The Board and Executive team remain focused on executing the strategic growth plans outlined at IPO, and in our regular trading updates. 2021 saw us scale revenue and expand our business model. We delivered a record revenue performance for the year, with Group revenue up +38% year-on-year to £2.2bn. On a two-year basis, THG has grown revenues +95%; effectively doubling the size of the business. Alongside significant revenue growth, FY 2021 saw the group acquire and successfully integrate several complementary businesses, deepening our vertical integration across both Beauty and Nutrition and expanding our reach to consumers across the globe.
At our most recent update on April 21st, the group highlighted its strong liquidity position with net cash of £44.4m at year end (excluding lease liabilities), cash of over £530m and a £170m undrawn revolving credit facility. The Group's bank facilities have long tenures, specifically, the €600m Term Loan B matures in December 2026 and the £170m revolving credit facility matures in December 2024.
We look forward to updating you during the second half of the year with the Group’s next scheduled trading update set for September 15th.